Literature DB >> 24706225

Neutropenic fever and sepsis: evaluation and management.

Kenneth V I Rolston1.   

Abstract

Neutropenia remains the predominant predisposing factor for infection in most cancer patients. Bacterial and fungal infections are common in this setting. Not all neutropenic patients have the same risk of developing severe infection or serious medical complications. Although all patients with neutropenia and fever should receive prompt, empiric antibiotic therapy, low-risk patients can be effectively managed without hospitalization-often with the administration of oral antibiotics. Other patients need hospital-based therapy. The emergence of resistant microorganisms has become a significant problem in neutropenic patients. Frequent epidemiologic surveys to detect the emergence of resistant organisms are recommended. Antibiotic stewardship and Infection Control Programs are important tools in combating resistant organisms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24706225     DOI: 10.1007/978-3-319-04220-6_6

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  4 in total

1.  Measurement of piperacillin plasma concentrations in cancer patients with suspected infection.

Authors:  Tobias Rachow; Verena Schlüter; Sibylle Bremer-Streck; Udo Lindig; Sebastian Scholl; Peter Schlattmann; Michael Kiehntopf; Andreas Hochhaus; Marie von Lilienfeld-Toal
Journal:  Infection       Date:  2017-05-17       Impact factor: 3.553

2.  Outcome of severe infections in afebrile neutropenic cancer patients.

Authors:  Ksenija Strojnik; Ksenija Mahkovic-Hergouth; Barbara Jezersek Novakovic; Bostjan Seruga
Journal:  Radiol Oncol       Date:  2016-02-10       Impact factor: 2.991

3.  Severe Drug-Induced Agranulocytosis Successfully Treated with Recombinant Human Granulocyte Colony-Stimulating Factor.

Authors:  Yohei Kubota; Ezekiel Wong Toh Yoon
Journal:  Case Rep Med       Date:  2018-01-23

4.  Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG-ALL-2015.

Authors:  Yiping Zhu; Rong Yang; Jiaoyang Cai; Jie Yu; Yanjing Tang; Yumei Chen; Ningling Wang; Hailong He; Xuedong Wu; Frankie W T Cheng; Lirong Sun; Yingyi He; Xiuli Ju; Xin Tian; Qun Hu; Runming Jin; Kaili Pan; Yongjun Fang; Xiaowen Zhai; Hui Jiang; Chi-Kong Li
Journal:  Cancer Med       Date:  2020-01-28       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.